Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

Medicinal Research Reviews

Volumn 28, Issue 3, 2008, Pages 372-412

  Li, Rongshi ^a,c   Morris, Stephan W ^b  

^a ChemBridge Research Laboratories   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c PHARMARON   (United States)

Author keywords

Anaplastic large cell lymphoma (ALCL); Anaplastic lymphoma kinase (ALK); Esophageal squamous cell carcinoma (esophageal SCC); Inflammatory myofibroblastic tumor (IMT); Midkine (MK); Pleiotrophin (PTN); Structure based drug design; Tyrosine kinase inhibitors

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 7 HYDROXYSTAUROSPORINE; ANAPLASTIC LYMPHOMA KINASE; BLEOMYCIN; BOSUTINIB; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; ERLOTINIB; GEFITINIB; GELDANAMYCIN; HERBIMYCIN A; HYBRID PROTEIN; IMATINIB; MIDKINE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NUCLEOPHOSMIN; PHOSPHOTRANSFERASE INHIBITOR; PLEIOTROPHIN; PREDNISONE; PROTEIN KINASE B INHIBITOR; PYRIMIDINONE DERIVATIVE; SORAFENIB; STAUROSPORINE; STAUROSPORINE DERIVATIVE; SUNITINIB; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; DRUG EFFECT; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GLIOBLASTOMA; HUMAN; LARGE CELL LYMPHOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA CELL GRANULOMA; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; NEOPLASMS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; SMALL MOLECULE LIBRARIES;

EID: 42549119526     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20109     Document Type: Review

References (349)

1. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 2000;103:211-225.
2. Kolibaba KS, Druker BJ. Protein kinases and cancer. Biochimica et Biophys Acta 1997;1333:F217-F248.
3. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-365.
4. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002;21:3314-3333.
5. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-1284.
6. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, A MS3. Oncogene 1994;9:1567-1574.
7. Mathew P, Morris SW, Kane JR, Shurtleff SA, Pasquini M, Jenkins NA, Gilbert DJ, Copeland NG. Localization of the murine homolog of the anaplastic lymphoma kinase (Alk) gene on mouse chromosome 17. Cytogenet Cell Genet 1995;70:143-144.
8. Pulford K, Mason DY. CD246 antigen. Leucocyte typing VII. In: Mason DY, et al. editor. White cell differentiation antigens. Oxford: Oxford University Press; 2002.
9. Sandlund JT, Pui CH, Sandlund JT, Pui C-H, Roberts WM, Santana VM, Morris SW, Berard CW, Hutchinson RE, Ribeiro R, Mahmoud H, Crist WM, Rafferty M, Raimondi SC. Clinicopathlogic features and tretament outcome of chidren with large cell lymphoma and the t(2;5)(p23;q35). Blood 1994;84:2467-2471.
10. Kadin ME, Morris SW. The t(2;5) in human lymphomas. Leuk Lymphoma 1998;29:249-256.
11. Kaneko Y, Frizzera G, Edamura S, Maseki N, Sakurai M, Komada Y, Tanaka H, Sasaki M, Suchi T, et al. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 1989;73:806-813.
12. Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis ED, Franklin WA, Rubin CM, Kadin ME, Vardiman JW. The t(2;5)(p23;q35): A recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 1989;3:866-870.
13. Rimokh R, Magaud JP, Berger F, Samarut J, Coiffier B, Germain D, Mason DY. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma'). Br J Haematol 1989;71:31-36.
14. Bitter MA, Franklin WA, Larson RA, McKeithan TW, Rubin CM, Le Beau MM, Stephens JK, Vardiman JW. Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). Am J Surg Pathol 1990;14:305-316.
15. Mason DY, Bastard C, Rimokh R, Dastague N, Huret JL, Kristoffersson U, Magaud JP, Nezelhof C, Tilly H, Vannier JP, Hemet J, Warnke R. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Brit J Haematol 1990;74:161-168.
16. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-449.
17. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997;14:2175-2188.
18. Loren CE, Scully A, Grabbe C, Edeen PT, Thomas J, McKeown M, Hunter T, Palmer RH. Identification and characterization of DAlk: A novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells 2001;6:531-544.
19. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, Mason DY. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody A LK1. Blood 1997;89:1394-1404.
20. Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, Mariame B. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000;156:1711-1721.
21. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001;276:16772-16779.
22. Stoica GE, Kuo A, Powers C, Bowden ET, Buchert-Sale E, Riegel AT, Wellstein A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002;277:35990-35999.
23. Daly NL, Scanlon MJ, Djordjevic JT, Kroon PA, Smith R. Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. Proc Natl Acad Sci USA 1995;92:6334-6338.
24. Beckmann G, Bork P. An adhesive domain detected in functionally diverse receptors. Trends Biochem Sci 1993;18:40-41.
25. Vernersson E, Khoo NKS, Henriksson ML, Roos G, Palmer RH, Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Exp Patterns 2006;6:448-461.
26. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A. ALK+ lymphoma: Clinico-pathological findings and outcome. Blood 1999;93:2697-2706.
27. Englund C, Loren CE, Grabbe C, Deleuil F, Varshney GK, Palmer RH. Jeb signals via the Dalk receptor tyrosine kinase to drive visceral muscle fusion. Nature 2003;425:512-516.
28. Lee H-H, Norris A, Weiss JB, Frasch M. Drosophila jelly belly signals through the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 2003;425:507-512.
29. Loren CE, Englund C, Grabbe C, Hallberg B, Hunter T, Palmer RH. A crucial role for the anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. EMBO J 2003;4:1-6.
30. Liao EH, Hung W, Abrams B, Zhen M. An SCF-like ubiquitin ligase complex that controls presynaptic differentiation. Nature 2004;430:345-350.
31. Mourali J, Benard A, Lourenco FC, Monnet C, Greenland C, Moog-Lutz C, Racaud-Sultan C, Gonzalez-Dunia D, Vigny M, Mehlen P, Delsol G, Allouche M. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic function are activated by caspase cleavage. Mol Cell Biol 2006;26:6209-6222.
32. Bredesen DE, Mehlen P, Rabizadeh S. Apoptosis and dependence receptors: A molecular basis for cellular addiction. Physiol Rev 2004;84:411-430.
33. Ruiz-Gomez M, Coutts N, Price A, Taylor MV, Bate M. Drosophila dumbfounded: A myoblast attractant essential for fusion. Cell 2000;102:189-198.
34. Porsch M, Hofmeyer K, Bausenwein BS, Grimm S, Weber BH, Miassod R, Pflugfelder GO. Isolation of a Drosophila T-box gene closely related to human T BX1. Gene 1998;212:237-248.
35. Varshney GK, Palmer RH. The bHLH transcripton factor Hand is regulated by Alk in the Drosophila embryonic gut. Biochem Biophys Res Commun 2006;351:839-846.
36. Bazigou E, Apitz H, Johansson J, Loren CE, Hirst EMA, Chen P-L, Palmer RH, Salecker I. Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila. Cell 2007;128:961-975.
37. Barbacid M. Structural and functional properties of the TRK family of neurotrophin receptors. Ann NY Acad Sci 1995;766:442-458.
38. Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem 1992;267:25889-25897.
39. Wellstein A, Fang WJ, Khatri A, Lu Y, Swain SS, Dickson RB, Sasse J, Riegel AT, Lippman ME. A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem 1992;267:2582-2587.
40. Chauhan AK, Li YS, Deuel TF. Pleiotrophin transforms NIH-3T3 cells and induces tumors in nude mice. Proc Natl Acad Sci USA 1993;90:679-682.
41. Schulte AM, Wellstein A. Pleiotrophin and related molecules. Tumour angiogenesis. Oxford, New York, Tokyo: Oxford University Press; 1997.
42. Kadomatsu K, Huang RP, Suganuma T, Murata F, Muramatsu T. A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in a spatially and temporally controlled manner during mouse embryogenesis. J Cell Biol 1990;110:607-616.
43. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004;204:127-143.
44. Ichihara-Tanaka K, Oohira A, Rumsby M, Muramatsu T. Neuroglycan C is a novel midkine receptor involved in process elongation of oligodendroglial precursor-like cells. J Biol Chem 2006;281:30857-30864.
45. Kojima S, Inui T, Muramatsu H, Suzuki Y, Kadomatsu K, Yoshizawa M, Hirose S, Kimura T, Sakakibara S, Muramatsu T. Dimerization of midkine by tissue transglutaminase and its functional implication. J Biol Chem 1997;272:9410-9416.
46. Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M. A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 or midkine in the high affinity binding to PTPzeta. J Biol Chem 1999;274:12474-12479.
47. Matsubara S, Take M, Pedraza C, Muramatsu T. Mapping and characterization of a retinoic acid-responsive enhancer of midkine, a novel heparin-binding growth/differentiation factor with neurotrophic activity. J Biochem (Tokyo) 1994;115:1088-1096.
48. Muramatsu T. Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumourigenesis. J Biochem (Tokyo) 2002;132:359-371.
49. Muramatsu H, Zou K, Sakaguchi N, Ikematsu S, Sakuma S, Muramatsu T. LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun 2000;270:936-941.
50. Muramatsu H, Zou P, Suzuki H, Oda Y, Chen GY, Sakaguchi N, Sakuma S, Maeda N, Noda M, Takada Y, Muramatsu T. alpha4beta1- and alphabeta1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci 2004;117:5404-5415.
51. Obata Y, Kikuchi S, Lin Y, Yagyu K, Muramatsu T, Kumai H. Tokyo Research Group on Prevention of Gastric Cancer. Serum midkine concentrations and gastric cancer. Cancer Sci 2005;96:54-56.
52. Salama RH, Muramatsu H, Zou P, Okayama M, Muramatsu T. Midkine, a heparin-binding growth factor, produced by the host enhances metastasis of Lewis lung carcinoma. Cancer Lett 2006;233:16-20.
53. Zou P, Muramatsu H, Miyata T, Muramatsu T. Midkine, a heparin-binding growth factor, is expressed in neural precursor cells and promotes their growth. J Neurochem 2006;99:1470-1479.
54. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996;56:2515-2518.
55. Weiss JB, Suyama KL, Lee HH, Scott MP. Jelly belly: A Drosophila LDL receptor repeat-containing signal required for mesoderm migration and differentiation. Cell 2001;107:387-398.
56. Englund C, Birve A, Falileeva L, Grabbe C, Palmer RH. Miple1 and miple2 encode a family of MK/PTN homologues in Drosophila melanogaster. Dev Genes Evol 2006;216:10-18.
57. Bowden ET, Stoica GE, Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 2002;277:35862-35868.
58. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002;277:14153-14158.
59. Czubayko F, Schulte AM, Berchem GJ, Wellstein A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA 1996;93:14753-14758.
60. Schulte AM, Lai S, Kurtz A, Czubayko F, Riegel AT, Wellstein A. Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus. Proc Natl Acad Sci USA 1996;93:14759-14764.
61. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997;57:1814-1819.
62. Beecken WD, Kramer W, Joans D. New molecular mediators in tumor angiogenesis. J Cell Mol Med 2000;4:262-269.
63. Christman KL, Fang O, Kim AJ, Sievers RE, Fok HH, Candia AF, Colley KJ, Herradon G, Ezquerra L, Deuel TF, Lee RJ. Pleiotrophin induces formation of functional neovasculature in vivo. Biochem Biophys Res Commun 2005;332:1146-1152.
64. Dirks WG, Fahnrich S, Lis Y, Becker E, MacLeod RA, Drexler HG. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 2002;100:49-56.
65. Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J, Creminon C, Vigny M. Activation and inhibiton of anaplastic lymphoma kinase receptor tyrosine kinase activity by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005;280:26039-26048.
66. Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, Deuel TF. Pleiotrophin signals increased tyrosine phosphorylation of beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci USA 2000;97:2603-2608.
67. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). J Biol Chem 1996;271:21446-21452.
68. Raulo E, Julkunen I, Merenmies J, Pihlaskari R, Rauvala H. Secretion and biological activities of heparin-binding growth-associated molecule. Neurite outgrowth-promoting and mitogenic actions of the recombinant and tissue-derived protein. J Biol Chem 1992;267:11408-11416.
69. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SR, Mischel PS. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem 2005;280:26953-26964.
70. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, Pelicci PG, Flenghi L. ALK expression defines a distinct group of T/null lymphomas with a wide morphological spectrum. Am J Pathol 1998;153:875-886.
71. Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D, Daines C, Coffin CM. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: A study of 135 cases. Mod Pathol 2002;15:931-938.
72. Pillay K, Govender D, Chetty R. ALK protein expression in rhabdomyosarcomas. Histopathology 2002;41:461-467.
73. Li X-Q, Hisaoka M, Shi D-R, Zhu X-Z, Hashimoto H. Expression of anaplastic lymphoma kinase in soft tissue tumors: An immunohistochemical and molecular study of 249 cases. Hum Pathol 2004;35:711-721.
74. Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A, Sakai R. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002;21:5823-5834.
75. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005;167:213-222.
76. Miyake I, Hakomori Y, Misu Y, Nakadate H, Matsuura N, Sakamoto M, Sakai R. Domain-specific function of ShcC docking protein in neuroblastoma cells. 2005;24:3206-3215.
77. Shao CK, Su ZL, Feng ZY, Rao HL, Tang LY. Significance of ALK gene expression in neoplasms and normal tissues. Ai Zheng 2002;21:58-62.
78. Grzelinski M, Bader N, Czubayko F, Aigner A. Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int J Cancer 2005;117:942-951.
79. Brodeur GM, Nakagawara A, Yamashira DJ, Ikegaki N, Liu NG, Azar CG, Lee CP, Evans AE. Expression of TRKA, TRKB and TRKC in human neuroblastomas. J Neurooncol 1997;31:49-55.
80. Eggert A, Ikegaki N, Liu XG, Brodeur GM. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma. Klin Paediatr 2000;212:200-205.
81. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, al Saati T, Cerretti DP, Morris SW, Mason DY. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997;89:1483-1490.
82. Hannah AL. Kinases as drug discovery targets in hematologic malignancies. Curr Mol Med 2005;5:625-642.
83. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphomaassociated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997;17:2312-2325.
84. Mason DY, Pulford KA, Bischof D, Kuefer MU, Butler LH, Lamant L, Delsol G, Morris SW. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res 1998;58:1057-1062.
85. Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 1995;28:15-24.
86. Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, Pierotti MA. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol 1995;15:6118-6127.
87. Greco A, Fusetti L, Miranda C, Villa R, Zanotti S, Pagliardini S, Pierotti MA. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene 1998;16:809-816.
88. Ybe JA, Brodsky FM, Hofmann K, Lin K, Liu SH, Chen L, Earnest TN, Fletterick RJ, Hwang PK. Clathrin self-assembly is mediated by a tandemly repeated superhelix. Nature 1999;399:371-375.
89. Motorin Y, Le Caer JP, Waller JP. Cysteinyl-tRNA synthetase from Saccharomyces cerevisiae. Purification, characterization and assignment to the genomic sequence YNL247w. Biochimie 1997;79:731-740.
90. Beardsley GP, Rayl EA, Gunn K, Moroson BA, Seow H, Anderson KS, Vergis J, Fleming K, Worland S, Condon B, Davies J. Structure and functional relationships in human pur H. Adv Exp Med Biol 1998;431:221-226.
91. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 1996;93:4181-4186.
92. Rosenwald A, Ott G, Pulford K, Katzenberger T, Kuhl J, Kalla J, Ott MM, Mason DY, Muller-Hermelink HK. t(1;2)(q21;p23) and t(2;3)(p23;q21): Two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood 1999;94:362-364.
93. Pulford K, Falini B, Cordell J, Rosenwald A, Ott G, Muller-Hermelink HK, MacLennan KA, Lamant L, Carbone A, Campo E, Mason DY. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma. Am J Pathol 1999;154:1657-1663.
94. Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S, Schlegelberger B, Peeters B, De Wolf-Peeters C, Wlodarska I, Morris SW. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000;95:2144-2149.
95. Ma Z, Hill DA, Collins MH, Morris SW, Sumagi J, Zhon M, Zuppan C, Bridge JA. Fusion of ALK to the Ran-binding protein 2 (RANBP2) in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003;37:98-105.
96. Tort F, Pinyol M, Pulford K, Roncador G, Hernandez L, Nayach I, Kluin-Nelemans HC, Kluin P, Touriol C, Delsol G, Mason D, Campo E. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 2001;81:419-426.
97. Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, Pelicci PG, Falini B. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 2000;60:793-798.
98. Souttou B, Carvalho NB, Raulais D, Vigny M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 2001;276:9526-9531.
99. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21:1038-1047.
100. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/nullcell lymphoma. J Immunol 2002;168:466-474.
101. Amin HA, Medeiros LJ, Ma Y, Feretski M, Das P, Leventaki V, Rassidakis GZ, O'Connor SL, McDonnell TJ, Lai R. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003;22:5399-5407.
102. Ouyang T, Bai R-Y, Bassermann F, von Klitzing C, Klumpen S, Miething C, Morris SW, Peschel C, Duyster J. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J Biol Chem 2003;278:30028-30036.
103. Rassidakis GZ, Oyarzo MP, Medeiros LJ. BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Blood 2003;102:1146-1147.
104. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R. Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004;23:5426-5434.
105. L down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood 2004;103:2787-2794.
106. Crockett DK, Lin Z, Elenitoba-Johnson KSJ, Lim MS. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 2004;23:2617-2629.
107. c-src to mediate its mtiogenicity. Blood 2004;103:1464-1471.
108. Gu T-L, Tothova Z, Scheijen B, Griffin JD, Gilliland DG Sternberg DW. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 2004;103:4622-4629.
109. Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, Higashihara M, Kadin ME, Watanabe T. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-κB activation in anaplastic large cell lymphoma. Cancer Cell 2004;5:353-364.
110. Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hhirsch E, Erba EB, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood 2005;106:3907-3916.
111. Bacchiocchi R, Baldanzi G, Carbonari D, Capomagi C, Colombo E, van Blitterswijk WJ, Graziani A, Fazioli F. Activation of α-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase. Blood 2005;106:2175-2182.
112. Bassermann F, von Klitzing C, Munch S, Bai R-Y, Kawaguchi H, Morris SW, Peschel C, Duyster J. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 2005;122:45-57.
113. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE, Inghirami G. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005;11:623-629.
114. Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AML, Tartai CJ, Mologni L, Scapozza L, Gambacorti-Passerini C, Pinna LA. Unique substrate specificity of anaplastic lymphoma kinase (ALK): Development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 2005;44:8533-8542.
115. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, Odum N, Wasik MA. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 2005;85:1544-1554.
116. Valbuena JR, Rassidakis GZ, Lin P, Atwell C, Georgakis GV, Younes A, Jones D, Medeiros LJ. Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol 2005;18:1343-1349.
117. Zhang W, McQueen T, Schober W, Rassidakis G, Andreef M, Konopleva M. Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia 2005;19:1977-1984.
118. Amin HM, Lin Q, Lai R. Jak3 contributes to the activation of ALK and Stat3 in ALK+ anaplastic large cell lymphoma. Lab Invest 2006;86:417-419.
119. Chikamori M, Fujimoto J, Tokai-Nishizumi N, Yamamoto T. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation. Oncogene 2006;26:2950-2954.
120. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 2006;108:2796-2803.
121. Han Y, Amin HM, Frantz C, Franko B, Lee J, Lin Q, Lai R. Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 2006;20:1602-1609.
122. Cussac D, Pichereaux C, Colomba A, Capilla F, Pont F, Gaits-Lacovoni F, Lamant L, Espinos E, Burlet-Schlitz O, Monsarrat B, Delsol G, Payrastre B. Proteomic analysis of anaplastic lymphoma cell lines: Identification of potential tumour markers. Proteomics 2006;6:3210-3222.
123. Duplantier MM, Lamant L, Sabourday F, de Reynies A, Delsol G, Espinos E. Serpin A1 is overexpressed in ALK+ anaplastic large cell lymphoma and its expression correlates with extranodal dissemination. Leukemia 2006;20:1848-1854.
124. Fawal M, Armstrong F, Ollier S, Dupont H, Touriol C, Monsarrat B, Delsol G, Payrastre B, Morello D. A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK. Blood 2006;108:2780-2788.
125. Honorat J-F, Ragab A, Lamant L, Delsol G, Ragab-Thomas J. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood 2006;107:4130-4138.
126. Hsu FY-Y, Johnston PB, Burke KA, Zhao Y. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res 2006;66:9002-9008.
127. Kuo AH, Stoica GE, Riegel AT, Wellstein A. Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase. Oncogene 2006;26:859-869.
128. Lim MS, Elenitoba-Johnson KSJ. Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma. Mol Cell Proteomics 2006;5:1787-1798.
129. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. Nucleophosmin/ anaplastic lymphoma kinse (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating ST AT3. Proc Natl Acad Sci USA 2006;103:9964-9969.
130. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 2007;26:813-821.
131. Oyarzo MP, Drakos E, Atwell C, Amin HM, Medeiros LJ, Rassidakis GZ. Intrinsic apoptotic pathway in anaplstic large cell lymphoma. Hum Pathol 2006;37:874-882.
132. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lomardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006;116:3171-3182.
133. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, Amin HM. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 2006;108:2407-2415.
134. Quintanilla-Martinez L, Pittaluga S, Miething C, Klier M, Rudelius M, Davies-Hill T, Anastasov N, Martinez A, Vivero A, Duyster J, Jaffe ES, Fend F, Raffeld M. NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein β in ALK-positive anaplastic large cell lymphoma. Blood 2006;108:2029-2036.
135. Turner SD, Yeung D, Hadfield K, Cook SJ, Alexander DR. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal 2007;19:740-747.
136. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret F-X, Rassidakis GZ. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006;66:6589-6597.
137. Kurzrock R, Gutterman J, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988;319:990-998.
138. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukaemia with a t(5;12) chromosomal translocation. Cell 1994;77:307-316.
139. Golub TR, Goga A, Barker G, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG. Oligomerization of the ABL tyrosine kinase by the ETS protein TEL in human leukaemia. Mol Cell Biol 1996;16:4107-4116.
140. Melo J. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-2384.
141. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukaemia. Science 1997;278:1309-1312.
142. Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ, Fletcher JA. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998;18:84-87.
143. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, Koduru P, Brody JP, Hawson G, Rodwell R, Doody ML, Carnicero F, Reiter A, Goldman JM, Melo JV, Cross NC. The t(8;22) in chronic myeloid leukemia fuses BCR to FGF R1: Transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001;98:3778-3783.
144. Bullrich F, Morris SW, Hummel M, Pileri S, Stein H, Croce CM. Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas. Cancer Res 1994;54:2873-2877.
145. Elmberger PG, Lozano MD, Weisenburger DD, Sanger W, Chan WC. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions. Blood 1995;86:3517-3521.
146. Mathew P, Sanger WG, Weisenburger DD, Valentine M, Valentine V, Pickering D, Higgins C, Hess M, Cui X, Srivastava DK, Morris SW. Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. Blood 1997;89:1678-1685.
147. Waggott W, Lo YM, Bastard C, Gatter KC, Leroux D, Mason DY, Boultwood J, Wainscoat JS. Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma. Br J Haematol 1995;89:905-907.
148. Wellmann A, Otsuki T, Vogelbruch M, Clark HM, Jaffe ES, Raffeld M. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription- polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. Blood 1995;86:2321-2328.
149. Simonitsch I, Panzer-Gruemayer ER, Ghali DW, Zoubek A, Radaszkiewicz T, Gadner H, Kovar H. NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Ki-1-positive anaplastic large cell lymphomas. Br J Haematol 1996;92:866-871.
150. Johnson PW, Leek J, Swinbank K, Angus B, Roberts P, Markham AF, Selby PJ, MacLennan KA. The use of fluorescent in situ hybridization for detection of the t(2;5)(p23;q35) translocation in anaplastic large-cell lymphoma. Ann Oncol 1997;8:65-69.
151. Shiota M, Fujimoto J, Taneka M, Satoh H, Ichinohasama R, Abe M, Nakano M, Yamamoto T, Mori S. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994;84:3648-3652.
152. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi J, Mikata A, Nanba K, Takami K, Takami S, Yamabe H, Takano Y, Izumo T, Nagatami T, Mohri N, Nasu K, Satoh H, Katano M, Fujimoto J, Yamamoto T, Mori S. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 1995;86:1954-1960.
153. Shiota M, Mori S. The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Leuk Lymphoma 1996;23:25-32.
154. Shiota M, Mori S. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Leukemia 1997;11 (Suppl 3):538-540.
155. Nakamura S, Shiota M, Nakagawa A, Yatabe Y, Kojima M, Motoori T, Suzuki R, Kagami Y, Ogura M, Morishima Y, Mizoguchi Y, Okamoto M, Seto M, Koshikawa T, Mori S, Suchi T. Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 1997;21:1420-1432.
156. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G. ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 1998;91:2076-2084.
157. Haralambieva E, Pulford KA, Lamant L, Pileri S, Roncador G, Gatter KC, Delsol G, Mason DY. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. Br J Haematol 2000;109:584-591.
158. Lamant L, Meggetto F, Al Saati T, Brugieres L, de Paillerets BB, Dastugue N, Bernheim A, Rubie H, Terrier-Lacombe MJ, Robert A, Rigal F, Schlaifer D, Shiuta M, Mori S, Delsol G. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 1996;87:284-291.
159. Cataldo KA, Jalal SM, Law ME, Ansell SM, Inwards DJ, Fine M, Arber DA, Pulford KA, Strickler JG. Detection of t(2;5) in anaplastic large cell lymphoma: Comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am J Surg Pathol 1999;23:1386-1392.
160. Falini B, Pulford K, Pucciarini A, Carbone A, De Wolf-Peeters C, Cordell J, Fizzotti M, Santucci A, Pelicci PG, Pileri S, Campo E, Ott G, Delsol G, Mason DY. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999;94:3509-3515.
161. Pulford K, Roberton H, Banham AH, Hatton CS, Mason DY. Immunochemical studies of antigenic lymphoma-associated proteins. BrJ Haematol 2002;116:135-141.
162. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Pulford K, Willemze R, Falini B, Chott A, Meijer CJ. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 2000;53:445-450.
163. Pulford K, Roberten HM, Jones M. Antibody techiques used in the study of anaplastic lymphoma kinase-positive ALCL. Methods Mol Med 2005;115:271-294.
164. Falini B. Anaplastic large cell lymphoma: Pathological, molecular and clinical features. Br J Haematol 2001;114:741-760.
165. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: Clinical value of their detection by immunocytochemistry. Blood 2002;99:409-426.
166. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-3695.
167. Delsol G, Ralfkaier E, Stein H, Wright D, Jaffe ES. Anaplastic large cell lymphoma. Pathology and genetics. In: Jaffe E, et al. editors. World Health Organisation of tumours. Tumours of haematopoietic and lymphoid tissues. Lyon: World Health Organisation of tumours. International Agency for Research on Cancer (IACR); 2001.
168. Kinney MC, Kadin ME. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am J Clin Pathol 1999;11LS56-S67.
169. Morris SW, Xue L, Ma Z, Kinney MC. Alk+ CD30+ lymphomas: A distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol 2001;113:275-295.
170. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913-3921.
171. Skinnider BF, Connors JM, Sutcliffe SB, Gascoyne RD. Anaplastic large cell lymphoma: A clinicopathologic analysis. Hematol Oncol 1999;17:137-148.
172. Cheuk W, Hill RW, Bacchi C, Dias MA, Chan JK. Hypocellular anaplastic large cell lymphoma mimicking inflammatory lesions of lymph nodes. Am J Surg Pathol 2000;24:1537-1543.
173. Jhala DN, Medeiros LJ, Lopez-Terrada D, Jhala NC, Krishnan B, Shahab I. Neutrophil-rich anaplastic large cell lymphoma of T-cell lineage. A report of two cases arising in HIV-positive patients. Am J Clin Pathol 2000;114:478-482.
174. Piccaluga PP, Ascani S, Fraternali Orcioni G, Piccioli M, Pileri A Jr, Falini B, Pileri S. Anaplastic lymphoma kinase expression as a marker of malignancy. Application to a case of anaplastic large cell lymphoma with huge granulomatous reaction. Haematologica 2000;85:978-981.
175. Ponzoni M, Terreni MR, Ferreri AJM, Gerevini S, Anzalone N, Valle M, Pizzolito S, Arrigoni G. Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): The first case with a combination of 'not common' variants. Ann Oncol 2002;13:1827-1832.
176. Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000;14:1533-1559.
177. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001;20:5623-5637.
178. Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, Lui MY, Colleoni GW, Antonescu CR, Ladanyi M, Morris SW. Fusion of the ALK gene to the clathrin heavy chain gene,CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001;159:411-415.
179. Yamamoto H, Kohashi K, Oda Y, Tamiya S, Takahashi Y, Kinoshita Y, Ishizawa S, Kubota M, Tsuneyoshi M. Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene. Pathol Int 2006;56:584-590.
180. Brugieres L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, Pondarre C, Leverger G, Devalck C, Rodary C, Delsol G, Hartmann O. CD30+ anaplastic large-cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998;92:3591-3598.
181. Brugieres L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C, Schmitt C, Landmann J, Patte C, Terrier-Lacombe MJ, Delsol G, Hartmann O. Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children-A report from the French Society of Pediatric Oncology. Ann Oncol 2000; 53-58.
182. Fiorani C, Vinci G, Sacchi S, Bonaccorsi G, Artusi T. Primary systemic anaplastic large-cell lymphoma (CD30+): Advances in biology and current therapeutic approaches. Clin Lymphoma 2001;2:29-37.
183. Gascoyne RD. Therapeutic consequences of pathology and prognostic factors in aggressive NHL - Analysis of ALCL. Ann Hematol 2001;80:B45-B48.
184. Herling M, Luthra R, Pugh W, Romaguera J, Morris SW, Falini B, Cabanillas F, Sarris AH. The t(2;5) and failure-free survival (FFS) of adults with anaplastic large cell lymphoma (ALCL). Blood 1998;92:224b.
185. Hutchison RE, Banki K, Shuster JJ, Barrett D, Dieck C, Berard CW, Murphy SB, Link MP, Pick TE, Laver J, Schwenn M, Mathew P, Morris SW. Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol 1997;8:37-42.
186. Le Deley MC, Reiter A. Prognostic factors in childhood anaplastic large cell lymphoma: Results of the European Intergroup Study. Ann Oncol 1999;10:28.
187. Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, Lazzarino M, Borroni G, Menestrina F, Santucci M. CD30/Ki-1-positive lymphoproliferative disorders of the skin - Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group. J Clin Oncol 1993;13:1343-1354.
188. Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R, Mori N, Kojima M, Yoshino T, Yamabe H, Shiota M, Mori S, Ogura M, Hamajima N, Seto M, Suchi T, Morishima Y, Nakamura S. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000;96:2993-3000.
189. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: Differential diagnostic and prognostic aspects - A review. J Pathol 2003;200:4-15.
190. Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR. Anaplastic large cell lymphoma in childhood: Analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002;117:812-820.
191. Wood GS, Hardman DL, Boni R, Dummer R, Kim YH, Smoller BR, Takeshita M, Kikuchi M, Burg G. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Blood 1996;88:1765-1770.
192. ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJLM. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 2003;43:462-469.
193. Thompson MA, Stumph J, Henrickson SE, Rosenwald A, Wang Q, Olson S, Brandt SJ, Roberts J, Zhang X, Shyr Y, Kinney MC. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinse-negative anaplastic large cell lymphomas. Hum Pathol 2005;36:494-504.
194. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-1538.
195. Lamant L, de Reynies A, Duplantier M-M, Rickman DS, Sabourdy F, Giuriato S, Brugieres L, Gaulard P, Espinos E, Delsol G. Gene expression profiling of systemic anaplastic large cell lymphoma reveals differences depending on ALK status and two distinct morphological ALK+ subtypes. Blood 2007;109:2156-2164.
196. Willenbrock K, Kuppers R, Renne C, Brune V, Eckerle S, Weldmann E, Brauninger A, Hansmann M-L. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica 2006;91:596-604.
197. Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C. Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling. J Pathol 2006;210:155-162.
198. Kewalramani T, Zelenet AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S, Nimer SD, Moskowitz CH. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Brit J Haematol 2006;134:202-207.
199. Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, Mueller-Hermelink HK, Seymor JF, Horsman DE, Auvigne I, Espinos E, Siebert R, Delsol G. ALK-positive difuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of six cases. Blood 2003;102:2568-2571.
200. Chikatsu N, Kojima H, Suzukawa K, Shinagawa A, Nagasawa T, Ozav H, Yamashita Y, Mori N. ALK+, CD30-, CD20-large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol 2003;16:828-832.
201. De Paepe P, Baens M, van krieken H, Verhasselt B, Stul M, Simons A, Poppe B, Laureys G, Brons P, Vandenberghe P, Speleman F, Praet M, De Wolf-Peeters C, Marynen P, Wlodarska I. ALK activation by the CTLC-ALK fusion is a recurrent event in B-cell lymphoma. Blood 2003;102:2638-2641.
202. Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, Morris SW, Kennedy W, Jones SC, Sandlund JT. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: Report of two cases. Blood 2003;102:2642-2644.
203. Reichard KK, McKenna RW, Kroft SH. ALK-positive B-cell lymphoma: A report of three cases. Mod Pathol 2003;16:250A.
204. Banham AH, Turley H, Pulford K, Gatter K, Macon DY. The plasma cell associated antigen detectable by antibody VS38 is the p63 regulatory endoplasmic reticulum protein. J Clin Pathol 1997;50:485-489.
205. Touriol C, Greenland C, Lamant L, Pulford K, Bernard F, Rousset T, Mason DY, Delsol G. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95:3204-3207.
206. Wang WY, Ma ZG, Li GD, Liu WP, Zhong L, Wang Y, Li JM, Li L, Jiang W, Tang Y, Liao DY. Diffuse large B-cell lymphoma with expression of anaplastic lymphoma kinase protein: Clinicopathologic and immunohistochemical study of 5 cases. Zhonghua Bing Li Xue Za Zhi 2006;35:529-534.
207. Teruya-Feldstein J. Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep 2005;7:357-363.
208. Beljaards RC, Meijer CJ, Van der Putte SC, Hollema H, Geerts ML, Bezemer PD, Willemze R. Primary cutaneous T-cell lymphoma: Clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol 1993;172:53-60.
209. Beylot-Barry M, Lamant L, Vergier B, de Muret A, Fraitag S, Delord B, Dubus P, Vaillant L, Delaunay M, MacGrogan G, Beylot C, de Mascarel A, Delsol G, Merlio JP. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol 1996;149:483-492.
210. Beylot-Barry M, Groppi A, Vergier B, Pulford K, Merlio JP. Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations. Blood 1998;91:4668-4676.
211. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999;59:2776-2780.
212. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001;14:569-576.
213. Nascimento AF, Ruiz R, Hornick JL, Fletcher CD. Calcifying fibrous "pseudotumor": Clinicopathologic study of 15 cases and analysis of its relationship to inflammatory myofibroblastic tumor. Int J Surg Pathol 2002;10:189-196.
214. Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, Hill DA. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: A comparative immunohistochemical study. Am J Surg Pathol 2001;25:1364-1371.
215. Ladanyi M. Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms. Am J Pathol 2000;157:341-345.
216. Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000;157:377-384.
217. Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, De Wolf-Peeters C, Pauwels P, Hagemeijer A, Marynen P. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002;34:354-362.
218. Panagopoulos I, Nilsson T, Domanski HA, Isaksson M, Lindblom P, Mertens F, Mandahl N. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 2006;118:1181-1186.
219. Yousem SA, Shaw H, Cieply K. Involvement of 2p23 in pulmonary inflammatory pseudotumors. Hum Pathol 2001;32:428-433.
220. Sirvent N, Hawkins AL, Moeglin D, Coindre JM, Kurzenne JY, Michiels JF, Barcelo G, Turc-Carel C, Griffin CA, Pedeutour F. ALK probe rearrangement in a t(2;11;2)(p23;p15;q31) translocation found in a prenatal myofibroblastic fibrous lesion: Toward a molecular definition of an inflammatory myofibroblastic tumor family? Genes Chromosomes Cancer 2001;31:85-90.
221. Chan JK, Cheuk W, Shimizu M. Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am J Surg Pathol 2001;25:761-768.
222. Sigel JE, Smith TA, Reith JD, Goldblum JR. Immunohistochemical analysis of anaplastic lymphoma kinase expression in deep soft tissue calcifying fibrous pseudotumor: Evidence of a late sclerosing stage of inflammatory myofibroblastic tumor? Ann Diagn Pathol 2001;5:10-14.
223. Chun YS, Wang L, Nascimento AG, Moir CR, Rodeberg DA. Pediatric inflammatory myofibroblastic tumor: Anaplastic lymphoma kinase (ALK) expression and prognosis. Pediatr Blood Cancer 2005;45:796-801.
224. Mergan F, Jaubert F, Sauvat F, Hartmann O, Lortat-Jacob S, Revillon Y, Nihoul-Fekete C, Sarnacki S. Inflammatory myofibroblastic tumor in children: Clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis. J Ped Surg 2005;40:1581-1586.
225. Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA. Inflammatory myofibroblastic tumor of the uterus. Am J Surg Pathol 2005;29:1348-1355.
226. Montgomery EA, Shuster DD, Burkart AL, Esteba JM, Sgrignoli A, Elwood L, Vaughn DJ, Griffin CA, Epstein JI. Inflammatory myofibroblastic tumors of the urinary tract: A clinicopathologic study of 46 cases, including a malignant example of inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol 2006;30:1502-1512.
227. Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, Abnet C, Yazdznbod M, Karkhane AA, Salekdeh GH. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006;12:7104-7112.
228. Du X-L, Hu H, Lin D-C, Xia S-H, Shen X-M, Zhang Y, Luo M-L, Feng Y-B, Cai Y, Xu X, Han Y-L, Zhan Q-M, Wang M-R. Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J Mol Med 2007;85:863-875.
229. Aklilu M, Ilson DH. Targeted agents and esophageal cancer - The next step? Semin Radiat Oncol 2007;17:62-69.
230. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004;199:330-358.
231. Pulford K, Lamant L, Espinos E, Jiang Z, Xue L, Turturro F, Delsol G, Morris SW. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 2004;61:2939-2953.
232. Coluccia AML, Gunby RH, Tartari CJ, Scapozza L, Gambacorti-Passerini C, Passoni L. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Expert Opin Ther Targets 2005;9:515-532.
233. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY, Morris SW. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997;90:2901-2910.
234. Miething C, Grundler R, Fend F, Hoepfl J, Mugler C, von Shcilling C, Morris SW, Peschel C, Duyster J. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene 2003;22:4642-4647.
235. Miething C, Grundler R, Mugler C, Peschel C, Duyster J. A new method of retroviral lineage specific expression utilizing the Cre/Lox system induces T-lymphoid malignancy in a mouse model of ALCL. Blood 2004;104: Abstract 348.
236. Miething C, Peschel C, Duyster J. Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: The role of murine models in defining pathogenesis and treatment options. Curr Drug Targets 2006;7:1329-1334.
237. Turner SD, Alexander DR. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 2005;19:1128-1134.
238. Chiarle R, Gong JZJ, Guasparri I, Pesci A, Cai J, Liu J, Simmons WJ, Dhall G, Howes J, Piva R, Inghirami G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003;101:1919-1927.
239. Turner SD, Tooze R, Maclennan K, Alexander DR. Vav promoter-regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 2003;22:7750-7761.
240. Turner SD, Merz H, Yeung D, Alexander DR. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res 2006;26:3275-3279.
241. Jager R, Hahne J, Jacob A, Egert A, Schenkel J, Wernert N, Schorle H, Wellmann A. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res 2005;25:3191-3196.
242. Dirks WG, Zaobrski M, Jager K, Challier C, Shiota M, Quentmeier H, Drexler HG. The t(2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: Absence of t(2;5) in Hodgkin-analogous cell lines. Leukemia 1996;10:142-149.
243. Pasqualucci L, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito L, Falini B, Kadin ME. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood 1995;85:2139-2146.
244. Lamant L, Espinos E, Duplantier M, Dastugue N, Robert A, Allouche M, Ragab J, Brousset P, Villalva C, Gascoyne RD, Al Saati T, Delsol G. Establishment of a novel anaplastic large-cell lymphoma cell line (COST) from a 'small-cell variant' of ALCL. Leukemia 2004;18:1693-1698.
245. Muto A, Nakagawa A, Shimomura Y, Kitagawa Y, Tsurusawa M. Antineoplastic agents for pediatric anaplastic large cell lymphoma: Vinblastine is the most effective in vitro. Leuk Lymphoma 2005;46:1489-1496.
246. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, Gray NS, Warmuth M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007;104:270-275.
247. Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006;107:689-697.
248. Christensen JG, Zou HY, Arango ME, Li Q, Lee J, McDonnell SR, Mroczkowski B, Bender S, Los G. A novel dual specificity inhibitor of c-Met and anaplastic lymphoma kinase (ALK) induces G1/S cell cycle arrest and apoptosis in NPM-ALK-positive anaplastic large cell lymphoma (ALCL) cells and complete regression in an experimental mouse model of ALCL. American Association for Cancer Research Annual Meeting 2006; Abstract LB-271.
249. Turturro F, Frist AY, Arnold MD, Seth P, Pulford K. Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27(Kip1). Oncogene 2001;20:4466-4475.
250. Huebinger G, Wehnes E, Xue L, Morris SW, Maurer U. Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large cell lymphoma. Exp Hematol 2003;31:226-233.
251. Ritter U, Damm-Welk C, Fuchs U, Bohle RM, Borkhardt A, Woessmann W. Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL). Oligonucleotides 2003;13:365-373.
252. Ergin M, Denning MF, Izban KF, Amin HM, Martinez RL, Saeed S, Alkan S. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp Hematol 2001;29:1082-1090.
253. Turturro F, Arnold MD, Frist AY, Pulford K. Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin Cancer Res 2002;8:240-245.
254. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002;1:31-36.
255. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-250.
256. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998;18:1517-1524.
257. Richter K, Buchner J. Hsp90: Chaperoning signal transduction. J Cell Physiol 2001;188:281-290.
258. Murphy PJ, Kanelakis KC, Galigniana MD, Morishima Y, Pratt WB. Stoichiometry, abundance, and functional significance of the hsp90/hsp70-based multiprotein chaperone machinery in reticulocyte lysate. J Biol Chem 2001;276:30092-30098.
259. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity. Invest New Drugs 1999;17:361-373.
260. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-217.
261. Turturro F, Frist AY, Arnold MD. Effects of the inhibition of NPM-ALK kinase activity by 17-allylamino-17-demethoxygeldanamycin (17-AAG). Blood 2001;98(11):456a, Abstract 1944.
262. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: Down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK+ CD30+ lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002;62:1559-1566.
263. Bonvini P, Rosa HD, Vignes N, Rosolen A. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: Role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 2004;64:3256-3264.
264. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol 2006;34:1670-1679.
265. Lai R, Rassidakis GZ, Lin Q, Atwell C, Medeiro LJ, Amin HM. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum Pathol 2005;36:939-944.
266. Shi X, Franko B, Frantz C, Amin HM, Lai R. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Brit J Haematol 2006;135:26-32.
267. Wan W, Albom MS, Lu L, Quail MR, Becknell NC, Weinberg LR, Reddy DR, Holskin BP, Angeles TS, Underiner TL, Meyer SL, Hudkins RL, Dorsey BC, Ator MA, Ruggeri BA, Cheng M. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006;107:1617-1623.
268. Li R, Xue L, Zhu T, Jiang Q, Cui X, Yan Z, McGee D, Wang J, Gantla VR, Pickens JC, McGrath D, Chucholowski A, Morris SW, Webb TR. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. J Med Chem 2006;49:1006-1015.
269. Zhu T, Yan Z, Chucholowski A, Webb TR, Li R. Polymer-supported synthesis of pyridine-focused libraries as inhibitors of anaplastic lymphoma kinase. J Comb Chem 2006;8:401-409.
270. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schadt M, Diehl V. Production of a monoclonal antibody specific for Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982;299:65-67.
271. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol 1999;90:157-164.
272. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H. CD30 (Ki-1) molecule: A new cytokine receptor of the tumour necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;87:3437-3441.
273. Huebinger GE, Muller E, Scheffran I, Schneider C, Hilde E, Singer BA, Sigg I, Graf J, Bergmann L. CD30-mediated cell cycle arrest associated with induced expression of p21CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 2001;20:590-598.
274. Koon HB, Junghans RP. Anti-CD30 antibody-based therapy. Curr Opin Oncol 2000;12:588-593.
275. Levi E, Wang Z, Petrogiannis-Haliotis T, Pfeifer WM, Kempf W, Drews R, Kadin ME. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: A possible mechanism for disease progression. J Invest Dermatol 2000;115:1034-1040.
276. Levi E, Pfeifer WM, Kadin ME. CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: Apoptosis or cell-cycle arrest? Blood 2001;98:1630-1632.
277. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000;96:4307-4312.
278. Mir SS, Richter BWM, Duckett CS. Strength of CD30 signal determines sensitivity to apoptosis. Blood 2001;99:1631-1632.
279. Nadali G, Micheletti M, Chilosi M, Sarris AH, Pizzolo G. Serum levels of the sCD30 molecules in anaplastic large cell lymphoma (ALCL): Relationship with the expression of ALK p80 protein. Blood 1999;94:511a.
280. Pasqualucci L, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito G, Falini B, Kadin ME. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saponin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30 anaplastic large-cell lymphoma. Blood 1995;85:2139-2146.
281. Pfeifer W, Levi E, Petrogiannis-Haliotis T, Lehmann L, Wang Z, Kadin ME. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Am J Pathol 1999;155:1353-1359.
282. Schneider C, Huebinger G. Pleiotropic signal transduction mediated by human C D30: A member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 2002;43:1355-1366.
283. Tian ZG, Longo DL, Funakoshi S, Asai O, Ferris DK, Widmer M, Murphy WJ. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 1995;55:5335-5341.
284. Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, Chace DF, Siegall CB, Francisco JA. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-3742.
285. Pulford K, Falini B, Banham AH, Codrington D, Roberton H, Hatton C, Mason DY. Immune response to the ALK oncogene tyrosine kinase in patients with anaplastic large cell lymphoma. Blood 2000;96:1605-1607.
286. + T-cell epitopes. Blood 2002;99:100-106.
287. Borisch B, Yerly S, Cerato CH, Schwaller J, Wacker P, Ozsahin AH, Brousse N, Hoessli DC. ALK-positive anaplastic large-cell lymphoma: Strong T and B anti-tumor responses may cause hypocellular aspects of lymph nodes mimicking inflammatory lesions. Eur J Haematol 2003;71:243-249.
288. Ait-Tahar K, Cerundolo V, Banham AH, Hatton C, Blanchard T, Kusec R, Becker M, Smith GL, Pulford K. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer 2006;118:688-695.
289. Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola M, Gianni AM, Gambacorti-Passerini C. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. Haematologica 2006;91:48-55.
290. Ait-Tahar K, Barnardo MCN, Pulford K. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res 2007;67:1898-1901.
291. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000;47:185-201.
292. Goepfert BJ, Brinkley BR. The centrosome-associated Aurora/Ipl-like kinase family. Curr Top Dev Biol 2000;49:331-342.
293. Winder WW. AMP-activated protein kinase: Possible target for treatment of type 2 diabetes. Diabetes Technol Ther 2000;2:441-448.
294. Wagman AS, Nuss JM. Current therapies and emerging targets for treatment of diabetes. Curr Pharm Des 2001;7:417-450.
295. Kirschenbaum F, Hsu SC, Cordell B, McCarthy JV. Glycogen synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels. J Biol Chem 2001;276:30701-30707.
296. Sanchez R, Sali A. Comparative protein structure modeling. Introduction and practical examples with modeler. Methods Mol Biol 2000;143:97-129.
297. Zheng WH, Kar S, Dor S, Quirion R. Insulin-like growth factor-1 (IGF-1): A neuroprotective trophic factor acting via the akt kinase pathway. J Neural Transm Suppl 2000;60:261-272.
298. Doherty AM. To market, to market - 2001. In: Doherty AM, editor-in-chief. Annual reports in medicinal chemistry. San Diego: Academic Press; 2002. pp 267-268.
299. Doherty AM. To market, to market - 2002. In: Doherty AM, editor-in-chief. Annual reports in medicinal chemistry. San Diego: Academic Press; 2003. pp 358-359.
300. Hegde S, Schmidt M. To market, to market - 2004. In: Doherty AM, editor-in-chief. Annual reports in medicinal chemistry. San Diego: Academic Press; 2005. pp 454-455.
301. Hegde S, Schmidt M. To market, to market - 2005. In: Wood A, editor-in-chief. Annual reports in medicinal chemistry. San Diego: Academic Press; 2006; pp 466-467.
302. Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007;50:409-424.
303. Li S, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu J, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C. Discovery of 5-[5-fluoro-2oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H- pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46:1116-1119.
304. Lambardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen M, Wityak J, Borzilleri RM. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661.
305. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-1934.
306. Bernards A, de la Monte SM. The ltk receptor tyrosine kinase is expressed in pre-B lymphocytes and cerebral neurons and uses a non-AUG translational initiator. EMBO J 1990;9:2279-2287.
307. Krolewski JJ, Dalla-Favera R. The ltk gene encodes a novel receptor-type protein tyrosine kinase. EMBO J 1991;10:2911-2919.
308. Snijders AJ, Haase VH, Bernards A. Four tissue-specific mouse ltk mRNAs predict tyrosine kinases that differ upstream of their transmembrane segment. Oncogene 1993;8:27-35.
309. Toyoshima H, Kozutsumi H, Maru Y, Hagiwara K, Furuya A, Mioh H, Hanai N, Takaku F, Yazaki Y, Hirai H. Differently spliced cDNAs of human leukocyte tyrosine kinase receptor tyrosine kinase predict receptor proteins with and without a tyrosine kinase domain and a soluble receptor protein. Proc Natl Acad Sci USA 1993;90:5404-5408.
310. Gunby RH, Tartari CJ, Porchia F, Donella-Deana A, Scapozza L, Gambacorti-Passerini C. An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. Haematologica 2005;90:988-990.
311. Sauville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM. Phase, I trial of 72-hour continuous infusion UCN-01 in patents with refractory neoplasms. J Clin Oncol 2001;19:2319-2333.
312. Toledo LM, Lydon NB, Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 1999;6:775-805.
313. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 1999;82:231-239.
314. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J. Tyrosine kinase inhibitors: From rational design to clinical trials. Med Res Rev 2001;21:499-512.
315. Webb TR, Lvovskiy D, Heinrich MC, Yee JWH. Discovery of novel inhibitors of tyrosine kinases. MEDI-228, 221st ACS National Meeting, San Diego, CA, United States, April 1-5, 2001.
316. Kuntz ID. Structure-based strategies for drug design and discovery. Science 1992;257:1078-1082.
317. Leach AR, Shoichet BK, Peishoff CE. Prediction of protein-ligand interactions. Docking and scoring: Success and gaps. J Med Chem 2006;49:5851-5855.
318. Mazur AK, Abagyan RA. New methodology for computer-aided modelling of biomolecular structure and dynamics. 1. non-cyclic structures. J Biomol Struct Dyn 1989;6:815-832.
319. Abagyan R, Argos P. Optimal protocol and trajectory visualization for conformational searches of peptides and proteins. J Mol Biol 1992;225:519-532.
320. Abagyan R, Totrov M, Kuznetsov D. ICM: A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J Comp Chem 1994;15:488-506.
321. Totrov M, Abagyan R. editors. Protein - Ligand docking as an energy optimization problem. Raffa RB, editor. The thermodynamics of receptor-inhibitor interactions. 2000. New York: Wiley and Sons.
322. Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L, Tartari CJ, Belloni V, Gambacorti-Passerini C, Scapozza L. Structural insights into the ATP binding pocket of the Anaplastic Lymphoma Kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. J Med Chem 2006;49:5759-5768.
323. Blencke S, Zeck B, Engkvist O, Greff Z, Orfi L, Horvath Z, Heri G, Ullrich A, Daub H. Characterization of conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 2004;11:691-701.
324. Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, Ubersax J, Biethrow J, Morgan DO, Shokat KM. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999;6:671-678.
325. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005;12:621-637.
326. Cavalli A, Dezi C, Folkers G, Scapozza L, Recanatini M. Three-dimensional model of the cyclin-dependent kinase 1 (CDK1): Ab initio active site parameters of molecular dynamic studies of CDKS. Proteins 2001;45:478-485.
327. Imbach P, Kawahara E, Konishi K, Matsuura N, Miyake T, Ohmori O, Roesel J, Teno N, Umemura I. Preparation of bis(arylamino)pyridine derivatives as antitumor agents. PCT Int Appl 2006;WO2006021454.
328. Baenteli R, Bernhard M, Buehlmayer P, Cooke NG, Duthaler R, Hinterding K, Thoma G, VanEis M, Von Matt A, Walliser L, Zenke G. Preparation of 2,4-di[(hetero)arylamino]pyrimidine derivatives as ZAP-70 and/or SYK inhibitors. PCT Int Appl 2005; WO2005026158.
329. Kawahara E, Miyake T, Roesel J. Preparation of pyrimidine compounds as FAK and/or ALK inhibitors. PCT Int Appl 2006; WO2006021457.
330. Choi H, Wang Z, Gray NS, Gu X, He X, He Y, Jiang T, Liu Y, Richmond W, Sim T, Yang K. Preparation of pyrrolopyrimidines and their analogs as protein kinase inhibitors. PCT Int Appl 2005; WO2005080393.
331. Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Dubenko L, Kennedy AR, Khoury RG, Kim AI, Mandlo JL, Peto CJ, Rice KD, Tsang TH. Preparation of pyrazolo[3,4-c]isoquinoline derivatives as anaplastic lymphoma kinase modulators. PCT int Appl 2005; WO2005009389.
332. Leahy JW, Lewis GL, Nuss JM, Ridgway BH, Sangalang JC. Preparation of thiazoles and analogs as anaplastic lymphoma kinase modulators. PCT Int Appl 2005; WO2005097765.
333. Vieth M, Sutherland JJ, Robertson DH, Campbell RM. Kinomics: Characterizing the therapeutically validated kinase space. Drug Discov Today 2005;10:839-846.
334. Weinmann H, Metternich R. Drug discovery process for kinase inhibitors. ChemBioChem 2005;6:455-459.
335. Palmer BD, Trumpp-Kallmeyer S, Fry DW, Nelson JM, Showalter HDH, Denny W. Tyrosine kinase inhibitors. 11. soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding. J Med Chem 1997;40:1519-1529.
336. Trumpp-Kallmeyer S, Rubin JR, Humblet C, Hamby JM, Showalter HDH. Development of binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J Med Chem 1998;41:1752-1763.
337. Traxler P, Hreen J, Mett H, Sequin U, Furet P. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem 1999;42:1018-1026.
338. Gill A. New lead generation strategies for protein kinase inhibitors - Fragment-based screening approaches. Mini Rev Med Chem 2004;4:301-311.
339. Hajduk PJ. Fragment-based drug design: How big is too big? J Med Chem 2006;49:6972-6976.
340. Nobel MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: Insights into drug design from structure. Science 2004;303:1800-1805.
341. Tauchi T, Ohyashiki K. The second generation of BCR-ABL tyrosine kinase inhibitors. Int J Hematol 2006;83:294-300.
342. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, Reddy MV, Reddy EP. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005;102:1992-1997.
343. Parang K, Sun G. Design strategies for protein kinase inhibitors. Curr Opin Drug Discov Devel 2004;7:617-629.
344. Bolos J. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors. Mini Rev Med Chem 2005;5:857-868.
345. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005;7:275-286.
346. Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene 2005;24:7493-7501.
347. Bilsland JG, Wheeldon A, Mead A, Znamenskiy P, Almond S, Waters KA, Thakur M, Beaumont V, Bonnert TP, Heavens R, Whiting P, McAllister G, Munoz-Sanjuan I. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 2007 fepub ahead of print].
348. Perez-Pinera P, Chang Y, Astudillo A, Mortimer J, Deuel TF. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun 2007;358:399-403.
349. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 [epub ahead of print].